In 2015, Johnson & Johnson announced a first-of-its-kind pilot partnership between Johnson & Johnson Innovative Medicine and the Division of Medical Ethics at New York University (NYU) Langone Health to form the Compassionate Use Advisory Committee (CompAC). This model is a novel approach that Johnson & Johnson employs globally to provide a fair, ethical evaluation of compassionate use requests for specific investigational medicines for patients with serious or life-threatening diseases.
CompAC, comprised of ethicists, physicians and patient representatives independently selected by NYU, provides recommendations to J&J IM on preapproval access plans and individual requests received at J&J IM. CompAC affirms Johnson & Johnson’s commitment to ensuring a transparent, ethical, and objective approach to reviewing compassionate use requests.
Below is an infographic illustrating the key results from our first CompAC pilot program. Click here to open this infographic as a PDF.
